Learn More About AD109: An Investigational Oral Tablet for OSA
| Estimated time to read:
The following content is part of a paid sponsorship and is not an endorsement by CHEST nor does it reflect the views or opinions of CHEST.
Apnimed is a late-stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. Apnimed envisions a new era where novel oral therapies simplify intervention, expand the reach of diagnosis and treatment, and help more people get the oxygen and restorative sleep needed to thrive.
Our lead product candidate, AD109, is an investigational once-daily at bedtime oral tablet for obstructive sleep apnea (OSA) that aims to revolutionize the treatment of OSA as the potentially first oral therapeutic that targets the neuromuscular dysfunction of OSA. Learn more about our vision and AD109 by visiting Apnimed at Booth #1119 throughout CHEST 2026.
We also invite you to join us for our featured scientific program: Clinical Overview of an Investigational Oral Tablet for OSA. Through an interactive format using clinical profiles, expert faculty Dr. Amir Sharafkhaneh and Dr. Dennis Hwang, will explore the heterogeneity of OSA and discuss why patients with similar apnea-hypopnea index (AHI) values can experience markedly different symptoms, oxygenation profiles, and overall disease burden. This highlights the importance of a multidimensional approach to OSA treatment response. The session will also showcase Phase 3 clinical findings for AD109 and highlight its projected path into the future of OSA patient care.
Learning Theater
- Date: Wednesday, October 21, 2026
- Time: 12:30–1:15 PM MST
- Location: Exhibit Hall, Learning Theater 3
- Lunch will be provided
Join us at Booth #1119 throughout CHEST 2026 to attend short expert-led scientific presentations, test your OSA IQ, engage with Medical Affairs colleagues, and learn about emerging research in OSA.
AD109 is investigational and not approved for use in any jurisdiction.
This is a non-CME event and does not qualify for CME, CE, or MOC credit. This event is not part of the official CHEST conference sessions. This event is not an endorsement by CHEST and does not reflect the views or opinions of CHEST.
